Circulation. Cardiovascular interventions
-
Circ Cardiovasc Interv · Oct 2013
Randomized Controlled TrialLeukocyte count is a modulating factor for the mortality benefit of bivalirudin in ST-segment-elevation acute myocardial infarction: the HORIZONS-AMI trial.
Although the reduction in mortality with bivalirudin compared with unfractionated heparin plus glycoprotein IIb/IIIa inhibitors in the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction (HORIZONS-AMI) trial has been attributed to lower rates of major bleeding, alternative mechanisms have not been investigated in depth. We sought to investigate whether there might be an interaction between white blood cell (WBC) count and bivalirudin for the risk of mortality, and whether this interaction is independent of major bleeding. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT00433966.
-
Circ Cardiovasc Interv · Oct 2013
Excimer laser-assisted removal of embedded inferior vena cava filters: a single-center prospective study.
Although chronically implanted inferior vena cava filters may result in filter-related morbidity, there is currently no routine option for removing such filters when they become firmly embedded along the vena cava endothelium. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT01158482.